TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00006916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ommaya reservoir

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
Study: NCT00832403

Intervention type: OTHER
Intervention: implants of polytetrafluoroethylene in tha nasal fossa
Description: surgical implants of polytetrafluoroethylene in the nasal fossa
Study: NCT05618106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: variations of the low FODMAP diet
Description: Cross-over of 3 interventions in IBS patients:~1. Low Polyol diet~2. Low FOS+GOS diet~3. Low FODMAP diet
Study: NCT02249546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine + PPI-amoxicillin-clarithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-amoxicillin-clarithromycin
Description: Triple therapy
Study: NCT04324814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Anti-PD-L1/TGFβ fusion protein
Study: NCT00564213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds
Description: Mitomycin 0.02%
Study: NCT04324814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Anti-PD-L1/TGFβ fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Anti-PD-L1/TGFβ fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Anti-PD-L1/TGFβ fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Anti-PD-L1/TGFβ fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Anti-PD-L1/TGFβ fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Anti-PD-L1/TGFβ fusion protein
Study: NCT03742895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg administered BID as two, 150 mg oral tablets.
Study: NCT03730259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based Tailored Intervention Preparation for Surgery
Description: A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
Study: NCT02363504

Intervention type: OTHER
Intervention: 7 Tesla MRI with memory task and non-invasive neurostimulation
Description: This is not an intervention, we investigate the neural mechanisms

Intervention type: OTHER
Intervention: 7 Tesla MRI with memory task and non-invasive neurostimulation
Description: This is not an intervention, we investigate the neural mechanisms
Study: NCT01085331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
Study: NCT00753896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 2.0mcg, once weekly
Study: NCT02350426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
Study: NCT03834831

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Coenzyme Q10
Study: NCT01085331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
Study: NCT02350426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-GE-180
Description: 18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
Study: NCT01085331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
Study: NCT03251716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: berberine
Description: berberine 300mg TID add-on for berberine adjunctive group
Study: NCT02350426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-GE-180
Description: 18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
Study: NCT00458510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
Description: treatment of up to 4 episodes of pain per day
Study: NCT02534389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fish oil
Description: 2,4g of EPA + DHA
Study: NCT00631046

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Daily dosage of 5 ml of fish oils from 9 months +/- 2weeks to 18 months +/- 4 weeks of age

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Description: Daily dosage of 5 ml of sunflower oil from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
Study: NCT03232593

Intervention type: DRUG
Intervention: Atezolizumab
Description: Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
Study: NCT00560391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
Description: Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
Study: NCT01199146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg by mouth per day
Study: NCT02664181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be given at 3mg/kg by IV every two weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given at 3mg/kg by IV every two weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral decitabine
Description: oral decitabine \~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine
Description: Oral THU \~10 mg/kg twice weekly on consecutive days
Study: NCT04342819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Sodium-Glucose Like Transporter 2 Inhibitor
Study: NCT03948061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry juice
Description: FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
Study: NCT02115607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity infusion
Description: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
Study: NCT02449278

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation involved-site radiotherapy (ISRT)
Description: 6 cycles modern CHOP chemotherapy followed consolidation involved-site radiotherapy (ISRT).~Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Consolidation involved-field radiotherapy (IFRT)
Description: 6 cycles modern CHOP chemotherapy followed consolidation involved-field radiotherapy (IFRT).~Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Patients in both arms will be given cyclophosphamide chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients in both arms will be given cyclophosphamide chemotherapy
Study: NCT04680559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCBI
Description: The topics covered in the sessions are: Week 1: Introduction to mindfulness and attention to breathing. Week 2. Open awareness of bodily sensations. Week 3: Work with thoughts, introductory theory and practice in attention to sounds. Week 4: Working with thoughts, advanced theory and practice in mental landscape. Week 5: Introductory theory and practice in labeling emotions. Session 6: Advanced theory in working with emotions and practice in difficult emotions. Week 7: Introductory theory on self-compassion and compassion. Practice in self-compassion. Week 8: Practice in compassion and active compassion (acts of kindness and shared humanity).
Study: NCT02449278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: Patients in both arms will be given doxorubicin chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Patients in both arms will be given doxorubicin chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: Patients in both arms will be given vincristine chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Patients in both arms will be given vincristine chemotherapy
Study: NCT03834831

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: Selenium
Study: NCT00765804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 with EyeGate® II System
Description: Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 with EyeGate® II System
Description: Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium citrate buffer solution with EyeGate® II System
Description: Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
Study: NCT02736344

Intervention type: DEVICE
Intervention: BioNIR Ridaforolimus Eluting Coronary Stent
Study: NCT00548145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: 2 mg by orally/day Duration: 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)
Description: duration: 12 months
Study: NCT01053039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal Saline
Description: The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
Study: NCT02324816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq CoolSculpting System
Description: The CoolSculpting System delivers non-invasive cooling for the reduction of subcutaneous fat.
Study: NCT03137225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Description: Neurally Adjusted Ventilatory Assist delivered via RAM cannula .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Description: Neurally Adjusted Ventilatory Assist delivered via RAM cannula .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Intermittent Positive Pressure Ventilation
Description: Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Intermittent Positive Pressure Ventilation
Description: Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
Study: NCT02402140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Intervention
Description: Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
Study: NCT00816192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-term electrical isolation of pulmonary veins
Description: All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long-term electrical isolation of pulmonary veins
Description: All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
Study: NCT03915470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XF-73
Description: XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match XF-73 nasal gel for colour and viscosity.
Study: NCT03933761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.
Study: NCT03160898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT02302872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTO System
Study: NCT00862693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.5ug/Biw
Study: NCT04090242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle
Description: Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
Study: NCT01969630

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEB
Description: Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PES
Description: Systematic Paclitaxel eluting stent angioplasty
Study: NCT00434109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Artery Embolizations
Description: 1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
Study: NCT01467921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h